Biotinylated Human KIR2DL2 Protein
Catalog No: KIR2DL2-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Biotinylated Human KIR2DL2 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues His22-His245 (UniProt accession: P43627).
Product Details
- Molecular Aliases
- NKAT-6;p58 NK receptor CL-43;CD158b1;KIR2DL2;CD158B1;NKAT6;p58NK receptor CL43
- Protein Length
- His22-His245
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 27.4 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human KIR2DL2 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
The purity of Biotinylated Human KIR2DL2 is greater than 90% as determined by SEC-HPLC.
Background
KIR2DL2 (2DL2, formerly NKAT6, designated CD158b) is a 348 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig‑like receptor (KIR) family. KIRs are expressed on human CD56dim NK cells and T cell subsets, and regulate effector functions in the innate immune system.KIR2DL2 is receptor on natural killer (NK) cells for HLA-Cw1, 3, 7, and 8 allotypes. Inhibits the activity of NK cells thus preventing cell lysis.
References
- Yoon S R, Kim T D, Choi I. Understanding of molecular mechanisms in natural killer cell therapy[J]. Experimental & Molecular Medicine, 2015, 47(2):e141.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.